+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drugs for the Treatment of Refractory Gout Market by Mechanism Of Action, Product Type, Route Of Administration, Distribution Channel, Dosage Form - Global Forecast to 2030- Product Image
Drugs for the Treatment of Refractory Gout Market by Mechanism Of Action, Product Type, Route Of Administration, Distribution Channel, Dosage Form - Global Forecast to 2030- Product Image
Sale

Drugs for the Treatment of Refractory Gout Market by Mechanism Of Action, Product Type, Route Of Administration, Distribution Channel, Dosage Form - Global Forecast to 2030

  • PDF Icon

    Report

  • 191 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6081639
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Introduction to the Refractory Gout Treatment Landscape

Refractory gout remains a significant challenge for healthcare providers and patients worldwide, characterized by persistent hyperuricemia and recurrent acute flares despite standard therapies. As novel biologics and small molecules emerge, the treatment landscape is evolving rapidly, demanding a deep understanding of mechanism, administration modalities, and regulatory influences. This executive summary distills the critical drivers reshaping the market, providing decision-makers with a concise yet comprehensive overview. Through systematic analysis of drug classes, product types, and patient pathways, stakeholders can anticipate shifts in clinical practice, optimize formulary decisions, and refine commercial strategies. By framing refractory gout not merely as a metabolic disorder but as an arena for therapeutic innovation, this introduction sets the stage for exploring transformative trends and actionable insights that will define the next phase of growth.

Transformative Shifts Reshaping the Therapeutic Landscape

Over the past decade, advances in biologic engineering and small-molecule design have transformed the outlook for patients unresponsive to conventional urate-lowering therapies. Monoclonal antibodies targeting interleukin pathways have unlocked new opportunities to modulate inflammation, while engineered uricases with improved pharmacokinetic profiles extend the reach of enzyme therapy. Concurrently, next-generation xanthine oxidase inhibitors and novel uricosurics are securing regulatory approvals, broadening the therapeutic arsenal. These breakthroughs reflect a broader shift toward precision medicine, where genetic markers and serum urate phenotypes guide treatment selection. In parallel, digital health platforms and remote monitoring tools facilitate real-time symptom tracking, driving patient adherence and enhancing clinical outcomes. Together, these developments signal a paradigm shift from one-size-fits-all management to tailored regimens that optimize efficacy, safety, and quality of life for refractory gout patients.

Analyzing the Cumulative Impact of US Tariffs in 2025

With the implementation of the 2025 tariff adjustments on pharmaceutical imports, cost structures for refractory gout drugs have experienced notable pressure. Tariff escalations on certain biologic components have driven incremental cost increases for manufacturers, prompting strategic reassessments of supply chains. To mitigate margin erosions, several companies have relocated manufacturing of key intermediates to tariff-exempt jurisdictions or negotiated volume-based rebate agreements with raw material suppliers. These supply chain adaptations have downstream implications for pricing negotiations with payers, potentially affecting formulary inclusion criteria. Moreover, clinicians face evolving reimbursement landscapes, as insurers recalibrate coverage policies to balance cost containment with patient access. In navigating this complex tariff environment, stakeholders must maintain agile sourcing strategies, monitor policy updates closely, and engage in proactive dialogue with payers to sustain treatment affordability and accessibility.

Key Segmentation Insights Driving Market Dynamics

Insight into therapeutic segmentation reveals distinct performance drivers across mechanism of action, product type, route of administration, distribution channel, and dosage form. Based on mechanism of action, evaluations encompass uricase agents subdivided into non-pegylated and pegylated formulations, uricosuric agents incorporating benzbromarone, lesinurad, and probenecid, alongside xanthine oxidase inhibitors such as allopurinol, febuxostat, and topiroxostat. This delineation underscores how molecular modifications enhance drug half-life, bioavailability, and immunogenicity profiles, directly influencing clinical adoption. When considering product type, branded offerings bifurcate into biosimilars and originator biologics, while off-patent generics compete on cost advantages. Route of administration further differentiates intravenous bolus and infusion therapies from oral capsules and tablets, as well as subcutaneous modalities delivered through auto-injectors or pre-filled syringes, each presenting unique patient adherence dynamics. Distribution channel analysis spans hospital pharmacies-both inpatient and outpatient-online pharmacies via direct-to-patient or electronic platforms, retail environments encompassing chain and independent outlets, and specialty networks differentiated by closed or open access. Finally, dosage form preferences range from hard gelatin and HPMC capsules to glass or polymer pre-filled syringes, film-coated and immediate-release tablets, and multi-dose or single-dose vials, spotlighting the importance of handling, storage, and administration considerations in formulary decision-making.

Key Regional Insights: Comparative Market Dynamics

Regional analyses spot contrasting trajectories across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets. In the Americas, integrated healthcare systems and robust reimbursement frameworks have accelerated adoption of high-cost biologics, driving investment in patient support programs that enhance long-term adherence. By contrast, Europe, Middle East & Africa exhibit heterogeneous regulatory and reimbursement environments, with some markets leveraging centralized approval pathways to expedite access, while others rely on health technology assessments to determine cost-effectiveness thresholds. In Asia-Pacific, expanding healthcare infrastructure, rising disposable incomes, and growing disease awareness underpin rapid uptake of next-generation therapies, though disparities in insurance coverage and out-of-pocket expenses pose access challenges. Cross-regional collaborations and licensing partnerships are emerging as strategic levers to harmonize clinical guidelines and broaden patient access, underscoring the value of global alignment in research, regulation, and market access planning.

Key Company Strategies and Competitive Landscape

Leading biopharmaceutical companies are advancing portfolios through strategic acquisitions, partnerships, and internal innovation pipelines. Established manufacturers of xanthine oxidase inhibitors continue to defend market share via incremental innovation, such as prodrug formulations and combination therapies. Meanwhile, emerging players specializing in biologic uricases leverage proprietary conjugation techniques to extend half-life and reduce immunogenicity, engaging in co-development agreements with academic institutions for novel biomarker validation. Uricosuric agent developers are exploring synergistic regimens that combine transporter inhibition with anti-inflammatory modalities to address flare management holistically. Additionally, contract manufacturing organizations are gaining prominence by offering end-to-end biologic development services, enabling smaller innovators to accelerate time-to-market. Through these collaborative networks, the industry is fostering a diversified value chain that balances cost efficiency with high-barrier scientific innovation.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize several actions to secure competitive advantage. First, integrating real-world evidence collection into clinical programs will strengthen payer negotiations and support differentiated value propositions. Second, strategic geographic expansion into under-penetrated Asia-Pacific and select EMEA markets can capture latent demand, provided launch strategies align with local reimbursement processes. Third, investing in supply chain resilience-by diversifying raw material suppliers and optimizing inventory buffers-will mitigate tariff-related cost pressures. Fourth, forging alliances with digital health providers to implement remote monitoring and adherence support tools will enhance patient outcomes and generate real-time data for product lifecycle management. Finally, cross-functional collaboration between R&D, market access, and commercial teams is essential to translate scientific innovation into scalable, patient-centric solutions that deliver sustained growth.

Rigorous Research Methodology and Data Sources

This analysis draws on a multi-pronged research methodology, combining primary interviews with key opinion leaders and decision-makers from clinical, regulatory, and payer organizations, alongside secondary data sourced from peer-reviewed journals, regulatory filings, and proprietary patent databases. Mechanism-specific therapeutic pipelines were mapped through clinical trial registries and corporate disclosures, while segment performance metrics were validated against real-world prescription databases. Tariff impact assessments relied on governmental trade notifications and import tariff schedules. Regional market dynamics were triangulated through national health authority reports and local distribution partner feedback. Throughout, qualitative insights were corroborated via iterative expert reviews to ensure accuracy and relevance, culminating in a robust framework that informs strategic decision-making without relying on speculative forecasting.

Conclusion: Synthesizing Trends and Future Directions

The refractory gout treatment landscape is undergoing a period of rapid transformation driven by scientific innovation, evolving reimbursement environments, and global supply chain complexities. Mechanism-based segmentation illuminates how advancements in uricase engineering, targeted inhibition, and combination regimens are redefining therapeutic pathways. Concurrently, regional nuances in regulatory and payer policies underscore the need for tailored market access strategies. By synthesizing primary and secondary data, this summary provides a coherent narrative on the forces shaping product development, competitive positioning, and patient outcomes. As stakeholders navigate tariff-induced cost pressures and leverage digital health integrations, the industry stands poised to deliver more effective, patient-centric solutions. Ultimately, sustained collaboration across the value chain will be critical in translating emerging science into optimal clinical care for patients with refractory gout.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Mechanism Of Action
    • Uricase Agents
      • Non-Pegylated Uricase
      • Pegylated Uricase
    • Uricosuric Agents
      • Benzbromarone
      • Lesinurad
      • Probenecid
    • Xanthine Oxidase Inhibitors
      • Allopurinol
      • Febuxostat
      • Topiroxostat
  • Product Type
    • Branded
      • Biosimilar
      • Originator
    • Generic
      • Off-Patent Generic
  • Route Of Administration
    • Intravenous
      • Bolus Injection
      • Infusion
    • Oral
      • Capsules
      • Tablets
    • Subcutaneous
      • Auto-Injector
      • Pre-Filled Syringe
  • Distribution Channel
    • Hospital Pharmacy
      • Inpatient
      • Outpatient
    • Online Pharmacy
      • Direct To Patient
      • E Pharmacy
    • Retail Pharmacy
      • Chain
      • Independent
    • Specialty Pharmacy
      • Closed Network
      • Open Network
  • Dosage Form
    • Capsule
      • Hard Gelatin
      • Hpmc
    • Pre Filled Syringe
      • Glass
      • Polymer
    • Tablet
      • Film Coated
      • Immediate Release
    • Vial
      • Multi Dose
      • Single Dose
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Takeda Pharmaceutical Company Limited
  • Horizon Therapeutics plc
  • AstraZeneca PLC
  • Ironwood Pharmaceuticals, Inc.
  • Amgen Inc.
  • Protalix BioTherapeutics, Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Drugs for the Treatment of Refractory Gout Market, by Drug Types
8.1. Introduction
8.2. Biologics
8.2.1. Fusion Proteins
8.2.2. Monoclonal Antibodies
8.3. Small Molecules
8.3.1. Interleukin Inhibitors
8.3.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
8.3.3. Urate-Lowering Therapies
8.4. Traditional Therapies
8.4.1. Colchicine
8.4.2. Corticosteroids
9. Drugs for the Treatment of Refractory Gout Market, by Route of Administration
9.1. Introduction
9.2. Intramuscular
9.3. Intravenous
9.4. Oral
9.5. Subcutaneous
10. Drugs for the Treatment of Refractory Gout Market, by End Users
10.1. Introduction
10.2. Clinics
10.2.1. Outpatient Clinics
10.2.2. Specialty Clinics
10.3. Hospitals
10.3.1. Private Hospitals
10.3.2. Public Hospitals
10.4. Online Pharmacies
10.5. Research Institutes
11. Drugs for the Treatment of Refractory Gout Market, by Age Group
11.1. Introduction
11.2. Adults (18-64)
11.2.1. Middle Age Adults (36-55)
11.2.2. Young Adults (18-35)
11.3. Geriatric (65+)
12. Drugs for the Treatment of Refractory Gout Market, by Mechanism of Action
12.1. Introduction
12.2. IL-1 Inhibitors
12.3. Urate Transporter Inhibitors
12.4. Xanthine Oxidase Inhibitors
13. Drugs for the Treatment of Refractory Gout Market, by Patient Type
13.1. Introduction
13.2. Acute Gout Flares
13.3. Chronic Refractory Gout
14. Americas Drugs for the Treatment of Refractory Gout Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Drugs for the Treatment of Refractory Gout Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Drugs for the Treatment of Refractory Gout Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. Ardea Biosciences, Inc.
17.3.3. AstraZeneca plc
17.3.4. Boehringer Ingelheim International GmbH
17.3.5. Chugai Pharmaceutical Co., Ltd.
17.3.6. CymaBay Therapeutics, Inc.
17.3.7. Horizon Therapeutics plc
17.3.8. Ipsen Group
17.3.9. Ironwood Pharmaceuticals, Inc.
17.3.10. Janssen Pharmaceuticals, Inc.
17.3.11. Novartis International AG
17.3.12. Regeneron Pharmaceuticals, Inc.
17.3.13. Savient Pharmaceuticals, Inc. (Acquired by Crealta Pharmaceuticals)
17.3.14. Sobi, Inc.
17.3.15. Takeda Pharmaceutical Company Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET MULTI-CURRENCY
FIGURE 2. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET MULTI-LANGUAGE
FIGURE 3. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URATE-LOWERING THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COLCHICINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MIDDLE AGE ADULTS (36-55), BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY YOUNG ADULTS (18-35), BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY GERIATRIC (65+), BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY IL-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY URATE TRANSPORTER INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ACUTE GOUT FLARES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CHRONIC REFRACTORY GOUT, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 59. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 84. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 86. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 87. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 88. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 89. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 90. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 92. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 93. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 94. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 95. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 96. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 97. CANADA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 98. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 99. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 101. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 102. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 104. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 105. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 106. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 107. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 108. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 109. MEXICO DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 124. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 126. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 129. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 130. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 136. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 137. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 138. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 139. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 140. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 142. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 143. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 144. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 145. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 146. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 147. AUSTRALIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 148. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 149. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 150. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 151. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 152. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 154. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 155. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 156. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 157. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 158. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 159. CHINA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 160. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 161. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 162. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 163. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 164. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 166. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 167. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 168. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 169. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 170. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 171. INDIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 172. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 173. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 174. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 175. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 176. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 178. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 179. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 180. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 181. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 182. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 183. INDONESIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 184. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 185. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 186. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 187. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 188. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 190. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 191. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 192. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 193. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 194. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 195. JAPAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 196. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 197. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 198. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 199. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 200. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 202. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 203. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 204. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 205. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 206. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 207. MALAYSIA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 208. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 209. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 210. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 211. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 212. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 214. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 215. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 216. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 217. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 218. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 219. PHILIPPINES DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 220. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 221. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 222. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 223. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 224. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 226. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 227. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 228. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 229. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 230. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 231. SINGAPORE DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 232. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 233. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 234. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 235. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 236. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 238. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 239. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 240. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 241. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 242. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 243. SOUTH KOREA DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 244. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 245. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 246. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 247. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 248. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 249. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 250. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 251. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 252. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 253. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 254. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 255. TAIWAN DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 256. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 257. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 258. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 259. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 260. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 262. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 263. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 264. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 265. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ADULTS (18-64), 2018-2030 (USD MILLION)
TABLE 266. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 267. THAILAND DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 268. VIETNAM DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
TABLE 269. VIETNAM DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 270. VIETNAM DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 271. VIETNAM DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY TRADITIONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 272. VIETNAM DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. VIETNAM DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 274. VIETNAM DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 275. VIETNAM DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 276. VIETNAM DRUGS FOR THE TREATMENT OF REFRACTORY GOUT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 277. VIETNAM DRUGS

Companies Mentioned

The companies profiled in this Drugs for the Treatment of Refractory Gout market report include:
  • Takeda Pharmaceutical Company Limited
  • Horizon Therapeutics plc
  • AstraZeneca PLC
  • Ironwood Pharmaceuticals, Inc.
  • Amgen Inc.
  • Protalix BioTherapeutics, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Chronic Refractory Gout - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Chronic Refractory Gout - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Chronic Refractory Gout - Pipeline Insight, 2025 - Product Image

Chronic Refractory Gout - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Gout Therapeutics - Global Strategic Business Report - Product Image

Gout Therapeutics - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Gout Therapeutics Market by Drug Class, Distribution Channel, Route of Administration, Therapy Line - Global Forecast to 2030 - Product Image

Gout Therapeutics Market by Drug Class, Distribution Channel, Route of Administration, Therapy Line - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Gout Therapeutics Market Report 2025 - Product Image

Gout Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.